US Centres for Medicare and Medicaid Services (CMS) has said it will pay for any COVID-19 vaccine that is authorised or approved by the US Food and Drug Administration to allow for "broad vaccine access and coverage for all Americans.", CNN reported on Thursday.
Also, the agency announced it will help cover a larger portion of the cost of new COVID-19 treatments that may be coming down the pipeline for Medicare recipients.
CMS administrator, Seema Verma, was quoted as saying during a briefing on 28 October: "There are several vaccines in Phase 3 trials, production and distribution plans are well underway, and CMS is doing its part by laying the essential groundwork for coverage and payment when a vaccine does arise. It'll be widely available and accessible to seniors and every American."
She added that while the US federal government is paying for the vaccine, insurers including Medicare, Medicaid and private plans must cover the cost of administering it.
Coiled Therapeutics doses first patient with optimised AO-252 formulation
CREATE Medicines agrees strategic research collaboration with Australia's Monash University
Ractigen Therapeutics IND application for RAG-1C receives FDA clearance
GlycoNex commences dosing in Phase I trial of GNX1021 in Japan
Datroway approved in EU for first-line metastatic triple-negative breast cancer
Karyopharm reports topline Phase 3 trial results in endometrial cancer
Kaigene and Taisho enter exclusive KG006 licensing agreement in Japan
Pfizer reports positive Phase 3 results for LITFULO in nonsegmental vitiligo
Octapharma to build USD1.5bn critical care manufacturing facility in Rock Hill, SC
Ractigen Therapeutics closes over USD31m financing for project advancement
10x Genomics and Lausanne University Hospital to collaborate on cancer care research
European Commission approves RINVOQ for severe alopecia areata
AbCellera and Vertex agree collaboration to develop multispecific T-cell engagers
Incyte's Opzelura approved in European Union for moderate atopic dermatitis